• Epidemiology and risk factors
• 30 min
  1. Epidemiology of COPD

  • Dr. David Mannino
• 36 min
  2. COPD in never smokers

  • Dr. Sundeep Salvi
• 43 min
  3. Genetics of chronic obstructive pulmonary disease (COPD)

  • Prof. Martin Tobin
• Phenotypes of COPD
• 44 min
  4. COPD and asthma: similarities and differences

  • Prof. Peter Barnes
• Pathophysiology and mechanisms of COPD
• 43 min
  5. The pathology of chronic obstructive pulmonary disease

  • Prof. James Hogg
• 63 min
  6. The continuum of COPD: a physiological perspective

  • Prof. Denis O'Donnell
• 47 min
  7. Inflammatory and immune mechanisms in COPD

  • Prof. Peter Barnes
• 44 min
  8. Mechanisms of COPD exacerbations and relation to exacerbation therapy

  • Prof. Wisia Wedzicha
• 39 min
  9. Protease-antiprotease balance

  • Prof. Robert Stockley
• Therapy and management
• 42 min
  10. Updates in chronic obstructive pulmonary disease (COPD)

  • Dr. Omar S. Usmani
• 45 min
  11. Long-acting bronchodilators in COPD

  • Prof. Bart Celli
• 54 min
  12. Treatment of COPD exacerbations

  • Prof. Antonio Anzueto
• 25 min
  13. Pulmonary rehabilitation: history, promise and problems

  • Prof. Richard Casaburi
• 29 min
  14. Lung volume reduction: advances in COPD

  • Dr. Nick Hopkinson
• 35 min
  15. New pharmacological therapies for COPD

  • Prof. Peter Barnes
• 32 min
  16. The Salford lung study in COPD

  • Dr. Dave Leather
• COPD case studies
• 11 min
  17. COPD treatment case I: COPD with “bronchitis attacks”

  • Dr. Janwillem Kocks
• 13 min
  18. COPD treatment case II: COPD with asthma as child

  • Dr. Janwillem Kocks
• 12 min
  19. COPD treatment case III: COPD with pre-diabetes

  • Dr. Janwillem Kocks
• 48 min
  20. Tailoring care for advanced COPD

  • Prof. Wissam Chatila
• Archived Lectures *These may not cover the latest advances in the field
• 59 min
  21. Alpha-1 antitrypsin deficiency: state of the art

  • Dr. Jamie Stoller
• 34 min
  22. Oxidative stress in COPD

  • Prof. William MacNee
• 24 min
  23. Managing co-morbidity in COPD

  • Dr. John Hurst
• 40 min
  24. Clinical phenotypes of COPD

  • Prof. Jørgen Vestbo
• 27 min
  25. Pulmonary rehabilitation: focusing on rehabilitative exercise

  • Prof. Richard Casaburi
• 36 min
  26. Genetics of COPD

  • Prof. Ian Hall

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Disclosure of interest
3. Why phenotype / subgroup? (1)
4. Why phenotype / subgroup? (2)
5. Phenotypes - one definition
6. The "frequent exacerbator"?
7. Eclipse study
8. Exacerbations frequency and severity
9. Multinomial regression
10. Eclipse study virtue
11. Stability of the exacerbator phenotype
12. Frequent exacerbator clinical review
13. There are no certainties
14. COPD equation
15. Venn diagram
16. COPD - phenotypes
17. First case of alpha1-antitrypsin deficiency 1963
18. Severe emphysema X-ray image
19. Severe emphysema CT scan
20. MicroCT of the lung study
21. Emphysema and small airways
22. Patients with COPD and asthma
23. Asthma and FEV1 decline
24. Chronic bronchitis
25. Mucus hypersecretion, and decline in FEV1
26. Predictive value of chronic bronchitis
27. COPD archetype
28. Important phenotypes in COPD
29. FEV1 decline, disease progression and severity
30. COPD activity
31. FEV1 decline by stage
32. A biomarker for disease activity in COPD
33. COPD lung function decline variety (1)
34. COPD lung function decline variety (2)
35. COPD biomarkers
36. Novel COPD phenotypes
37. How many phenotypes are there?
38. Conclusions

Topics Covered

• COPD
• More than one disease
• Definition of phenotypes
• Consideration of subgroups of COPD
• Traditional subgroupings
• Recently defined subgroupings
• What is the future of COPD?

Links

Series:

• Advances in Chronic Obstructive Pulmonary Disease (COPD)

Categories:

• Biochemistry
• Cell Biology
• Clinical Practice

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on July 31, 2012
• Archived on February 25, 2021

Financial Disclosures

• Prof. Jørgen Vestbo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.